½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1553430

È¿¼Ò DNA ÇÕ¼º ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ¼­ºñ½ºº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

Enzymatic DNA Synthesis Market Size, Share & Trends Analysis Report By Service (Oligonucleotide Synthesis, Gene Synthesis), By Application (Synthetic Biology, Genetic Engineering), By End-use, By Region, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

È¿¼Ò DNA ÇÕ¼º ½ÃÀå ¼ºÀå°ú µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è È¿¼Ò DNA ÇÕ¼º ½ÃÀåÀº 2030³â±îÁö 11¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 26.4%ÀÇ ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹ÙÀÌ¿ÀÀǾàÇ° ¿¬±¸ Áõ°¡, DNA ÇÕ¼º ±â¼úÀÇ ¹ßÀü, ÇÕ¼º»ý¹°ÇÐ ºÐ¾ßÀÇ È®´ë´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, Á¤¹Ð ÀÇ·á ¹× Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

COVID-19 ÆÒµ¥¹ÍÀº ÁÖ·Î Áø´Ü, ¹é½Å, Ä¡·áÁ¦ ¿¬±¸°³¹ßÀ» °¡¼ÓÈ­ÇÏ¿© ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃƽÀ´Ï´Ù. ¹ÙÀÌ·¯½ºÀÇ ½Å¼ÓÇÏ°í Á¤È®ÇÑ À¯Àüü ½ÃÄö½Ì°ú mRNA ¹é½Å °³¹ß¿¡ ´ëÇÑ ¼ö¿ä·Î ÀÎÇØ ÇÕ¼º DNA¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çß½À´Ï´Ù. ¶ÇÇÑ Àü¿°º´Àº ½Å¼ÓÇÏ°í È®Àå °¡´ÉÇϸç Á¤È®ÇÑ DNA ÇÕ¼º ¹æ¹ýÀÇ Á߿伺À» °­Á¶ÇÏ¿© È¿¼Ò ÇÕ¼º ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ¸¦ Áõ°¡½ÃÄ×½À´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 7¿ù DNA Script´Â ½Ã¸®Áî B ¶ó¿îµå¿¡¼­ 5,000¸¸ ´Þ·¯ÀÇ ÀÚ±ÝÀ» È®º¸ÇÏ¿© ÃÑ ÅõÀڱݾ×À» 8,900¸¸ ´Þ·¯·Î ²ø¾î¿Ã·Á ÇÕ¼º DNAÀÇ ¼¼°è °ø±ÞÀ» ÃËÁøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ°í ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È¿¡µµ ºñ¾àÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

¶ÇÇÑ, ÇÕ¼º»ý¹°ÇÐÀÇ ±Þ¼ÓÇÑ È®ÀåÀº È¿¼Ò DNA ÇÕ¼º¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½ÃÄ×½À´Ï´Ù. ÇÕ¼º »ý¹°, Ä¡·á¿ë ´Ü¹éÁú, ¹ÙÀÌ¿À ±â¹Ý ¹°Áú µî »õ·Î¿î »ý¹°ÇÐÀû ½Ã½ºÅÛÀ» °øÇÐÀûÀ¸·Î ±¸ÃàÇÏ´Â µ¥ »ç¿ëµÇ´Â º¹ÀâÇÑ À¯ÀüÀÚ ¼­¿­À» Á¤È®ÇÏ°í È¿À²ÀûÀ¸·Î ±¸ÃàÇØ¾ß ÇÒ Çʿ伺ÀÌ Áõ°¡ÇÏ°í Àֱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ È¿¼Ò DNA ÇÕ¼ºÀº ÇÕ¼º»ý¹°ÇÐÀÇ ¿ä±¸¸¦ ÃæÁ·ÇÏ´Â µ¥ ÇÊ¿äÇÑ ¼Óµµ, Á¤È®¼º, È®À强À» Á¦°øÇÏ¿© ¿¬±¸ÀÚµéÀÌ À¯ÀüÀÚ ÆíÁý, ´ë»ç °øÇÐ, ÇÕ¼º À¯ÀüüÇÐ µîÀÇ ºÐ¾ß¿¡¼­ Çõ½ÅÀ» ÀÌ·ê ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±×·¯³ª È¿¼ÒÀû DNA ÇÕ¼ºÀº Á¦Á¶ ºñ¿ëÀÌ ³ô°í ±â¼úÀûÀ¸·Î º¹ÀâÇϱ⠶§¹®¿¡ ±× È°¿ëÀÌ Á¦ÇÑµÉ ¼ö ÀÖ½À´Ï´Ù. È¿¼Ò ÇÕ¼º¿¡ ÇÊ¿äÇÑ Ã·´Ü Àåºñ, Ư¼ö ½Ã¾à ¹× Àü¹® Áö½ÄÀÌ ¿î¿µ ºñ¿ëÀÇ »ó½ÂÀ¸·Î À̾îÁö±â ¶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ, ÇÕ¼ºµÈ DNA ¿°±â¼­¿­ÀÇ Á¤È®¼º°ú È®À强À» º¸ÀåÇϱâ À§ÇÑ º¹ÀâÇÑ ÇÁ·Î¼¼½º´Â ±× È°¿ëÀ» ´õ¿í º¹ÀâÇÏ°Ô ¸¸µé°í, ÇÊ¿äÇÑ ±â¼úÀû ¿ª·®À» °®Ãá ÀڱݷÂÀ» °®Ãá ±â°ü ¹× Á¶Á÷À¸·Î¸¸ È°¿ëÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

È¿¼Ò DNA ÇÕ¼º ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ÇÕ¼º ºÎ¹®Àº À¯ÀüÀÚ ¿¬±¸, Áø´Ü, Ä¡·áÁ¦ °³¹ß µî ±¤¹üÀ§ÇÑ ÀÀ¿ë ºÐ¾ß·Î ÀÎÇØ 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÇÑÆí, À¯ÀüÀÚ ÇÕ¼ºÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • 2023³â¿¡´Â ÇÕ¼º»ý¹°ÇÐ ºÎ¹®ÀÌ ¾ÖÇø®ÄÉÀÌ¼Ç ºÎ¹® ½ÃÀå Á¡À¯À²À» Àå¾ÇÇÏ°í 27.5%ÀÇ °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â À¯ÀüÀÚ ÆíÁý, Ä¡·áÁ¦ ¹× »ê¾÷ »ý¸í°øÇп¡ ´ëÇÑ ÀÀ¿ëÀÌ Áõ°¡ÇÏ°í Àֱ⠶§¹®ÀÔ´Ï´Ù.
  • ÷´Ü Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, R&D ÅõÀÚ Áõ°¡, ÀǾàÇ° °³¹ß ¹× °³ÀÎ ¸ÂÃãÇü ÀǷḦ À§ÇÑ Ã·´Ü ¹ÙÀÌ¿ÀÅ×Å©³î·¯ÁöÀÇ Ã¤ÅÃÀ¸·Î 2023³â ¹ÙÀÌ¿À Á¦¾àȸ»ç°¡ ÃÖÁ¾ ¿ëµµ ºÎ¹®¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • ºÏ¹Ì´Â »ý¸í°øÇÐ, ÀÇ·á ¹× Ä¡·á ºÐ¾ßÀÇ °­·ÂÇÑ R&D, ¸·´ëÇÑ Á¤ºÎ ÀÚ±Ý Áö¿ø µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ 50.11%ÀÇ Á¡À¯À²·Î ½ÃÀåÀ» Áö¹èÇÏ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå È¿¼Ò DNA ÇÕ¼º ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óºÎ ½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå °ßÀÎ ¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • È¿¼Ò DNA ÇÕ¼º ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
    • COVID-19ÀÇ ¿µÇ⠺м®

Á¦4Àå È¿¼Ò DNA ÇÕ¼º ½ÃÀå : ¼­ºñ½ºº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ¼­ºñ½ºº° ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ È¿¼Ò DNA ÇÕ¼º ½ÃÀå ¼­ºñ½ºº° º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ È¿¼Ò DNA ÇÕ¼º ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¼­ºñ½ºº°, 2018-2030³â
  • ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ÇÕ¼º
  • À¯ÀüÀÚ ÇÕ¼º

Á¦5Àå È¿¼Ò DNA ÇÕ¼º ½ÃÀå : ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ¿ëµµº° ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ È¿¼Ò DNA ÇÕ¼º ½ÃÀå ¿ëµµº° º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ È¿¼Ò DNA ÇÕ¼º ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¿ëµµº°, 2018-2030³â
  • ÇÕ¼º»ý¹°ÇÐ
  • ¹é½Å °³¹ß
  • À¯ÀüÀÚ °øÇÐ
  • ±âŸ

Á¦6Àå È¿¼Ò DNA ÇÕ¼º ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ÃÖÁ¾ ¿ëµµ ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ È¿¼Ò DNA ÇÕ¼º ½ÃÀå ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ È¿¼Ò DNA ÇÕ¼º ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ÃÖÁ¾ ¿ëµµº°, 2018-2030³â
  • ¹ÙÀÌ¿ÀÀǾàÇ° ±â¾÷
  • Çмú¿¬±¸±â°ü
  • ¼öŹ¿¬±¸±â°ü

Á¦7Àå È¿¼Ò DNA ÇÕ¼º ½ÃÀå : ¼­ºñ½º, ¿ëµµ, ÃÖÁ¾ ¿ëµµº° Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ª ½ÃÀå ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø µ¿Ç⠺м®, 2018-2030³â
  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦8Àå °æÀï »óȲ

  • ±â¾÷/°æÀï ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ ½ÃÀå »óȲ ºÐ¼®, 2023³â
  • ±â¾÷ °³¿ä/»óÀå ±â¾÷
    • Telesis Bio Inc.
    • Twist Bioscience Corporation
    • GenScript Biotech Corp.
    • Evonetix
    • Ansa Biotechnologies, Inc.
    • Camena Bio
    • Molecular Assemblies
    • DNA Script
    • Touchlight
    • Kern Systems
ksm 24.09.24

Enzymatic DNA Synthesis Market Growth & Trends:

The global enzymatic DNA synthesis market is anticipated to reach USD 1.19 billion by 2030 and is expected to grow at a CAGR of 26.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing biopharmaceutical research, advancements in DNA synthesis, and the expanding field of synthetic biology are expected to propel market growth. Moreover, the rising demand for precision medicine and therapeutics is further anticipated to propel the demand for the market over the forecast period.

The COVID-19 pandemic positively impacted the market, primarily by accelerating research & development in diagnostics, vaccines, and therapeutics. The demand for rapid and accurate genomic sequencing of the virus and the development of mRNA vaccines significantly boosted the demand for synthetic DNA. In addition, the pandemic emphasized the significance of quick, scalable, and precise DNA synthesis methods, leading to increased investment in enzymatic synthesis technologies. For instance, in July 2020, DNA Script secured USD 50 million in funding for its Series B round, raising the total investment to USD 89 million, propelling their synthetic DNA supply worldwide. These factors have impelled the market's growth and are anticipated to propel exponentially over the forecast period.

In addition, the rapid expansion of synthetic biology further propelled the demand for enzymatic DNA synthesis. This is attributed to the growing need for precise and efficient construction of complex genetic sequences used in engineering novel biological systems, such as synthetic organisms, therapeutic proteins, and bio-based materials. Furthermore, enzymatic DNA synthesis offers the speed, accuracy, and scalability required to meet the demands of synthetic biology, enabling researchers to innovate in areas like gene editing, metabolic engineering, and synthetic genomics. These factors are thus projected to impel the market's growth over the forecast period.

However, the high cost of producing and technical complexity of enzymatic DNA synthesis might limit their accessibility. These challenges can create barriers to widespread adoption, as the advanced equipment, specialized reagents, and expertise required for enzymatic synthesis contribute to higher operational costs. In addition, the complicated processes involved in ensuring the accuracy and scalability of synthesized DNA sequences may further complicate its use, potentially restricting its availability to only well-funded institutions and organizations with the necessary technical capabilities. Thereby hampering the growth of the market over the forecast period.

Enzymatic DNA Synthesis Market Report Highlights:

  • The oligonucleotide synthesis segment held the largest market share in 2023 due to its wide applications, such as genetic research, diagnostics, and therapeutic development. On the other hand, gene synthesis is anticipated to grow at the fastest CAGR over the forecast period
  • In 2023, the synthetic biology segment is anticipated to dominate the market share for the application segment and is anticipated to grow at the fastest CAGR of 27.5%. This is attributed to the increasing application in gene editing, therapeutics, and industrial biotechnology
  • Biopharmaceutical companies dominated the end use segment with the largest share in 2023 due to the growing demand for advanced therapeutic solutions, increased investment in R&D, and the adoption of cutting-edge biotechnologies for drug development and personalized medicine
  • North America dominated the market with a share of 50.11% owing to factors such as strong R&D in biotechnology, medicine, and therapeutics, along with substantial government funding. Asia Pacific is anticipated to grow at the fastest CAGR over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Services
    • 1.2.2. Application
    • 1.2.3. End Use
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Enzymatic DNA Synthesis Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Growing biopharmaceutical industry
      • 3.2.1.2. Rising demand for precision medicine
      • 3.2.1.3. Increasing research in synthetic biology
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High costs of enzymatic DNA synthesis
  • 3.3. Enzymatic DNA Synthesis Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Enzymatic DNA Synthesis Market: Services Estimates & Trend Analysis

  • 4.1. Services Segment Dashboard
  • 4.2. Global Enzymatic DNA Synthesis Market Services Movement Analysis
  • 4.3. Global Enzymatic DNA Synthesis Market Size & Trend Analysis, by Services, 2018 - 2030 (USD Million)
  • 4.4. Oligonucleotide Synthesis
    • 4.4.1. Oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. Gene Synthesis
    • 4.5.1. Gene synthesis market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Enzymatic DNA Synthesis Market: Application Estimates & Trend Analysis

  • 5.1. Application Segment Dashboard
  • 5.2. Global Enzymatic DNA Synthesis Market Application Movement Analysis
  • 5.3. Global Enzymatic DNA Synthesis Market Size & Trend Analysis, by Application, 2018 - 2030 (USD Million)
  • 5.4. Synthetic Biology
    • 5.4.1. Synthetic biology market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Vaccine Development
    • 5.5.1. Vaccine development market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6. Genetic Engineering
    • 5.6.1. Genetic engineering market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Enzymatic DNA Synthesis Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Segment Dashboard
  • 6.2. Global Enzymatic DNA Synthesis Market End Use Movement Analysis
  • 6.3. Global Enzymatic DNA Synthesis Market Size & Trend Analysis, by End Use, 2018 - 2030 (USD Million)
  • 6.4. Biopharmaceutical Companies
    • 6.4.1. Biopharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Academic & Research Institutes
    • 6.5.1. Academic & research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Contract Research Organizations
    • 6.6.1. Contract research organizations market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Enzymatic DNA Synthesis Market: Regional Estimates & Trend Analysis by Services, Application, and End Use

  • 7.1. Regional Market Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 - 2030
  • 7.3. North America
    • 7.3.1. North America market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. UK market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. France market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Norway
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.9. Denmark
      • 7.4.9.1. Key country dynamics
      • 7.4.9.2. Regulatory framework
      • 7.4.9.3. Competitive scenario
      • 7.4.9.4. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Chile
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Chile market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2023
  • 8.4. Company Profiles/Listing
    • 8.4.1. Telesis Bio Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Twist Bioscience Corporation
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. GenScript Biotech Corp.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Evonetix
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Ansa Biotechnologies, Inc.
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Camena Bio
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Molecular Assemblies
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. DNA Script
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Touchlight
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Kern Systems
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦